Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2026 am IST			5-day change	1st Jan Change
55.92 ^USD	+0.43%		-1.03%	+27.58%

13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT

Transcript : Exelixis, Inc. Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-27-2026 03

Published on 05/28/2026 at 12:22 pm IST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Jeffrey Walch (Analysts)

Hi. My name is Jeffrey Walch. I co-lead the U.S. biotechnology coverage at Bernstein. Very excited today to have a nice fireside chat with Michael Morrissey,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Exelixis, Inc.

13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
02/07	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
02/07	Analyst recommendations: Adobe, AA, Nike, Exelixis…
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Value-Defensive Index	CI
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Growth-Defensive Index	CI
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Defensive Index	CI
22/06	Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	CI
09/06	Exelixis, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM
03/06	Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:05 AM
01/06	Wall Street Starts June on Edge
30/05	Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net	RE
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026	CI
28/05	Exelixis, Inc. Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-27-2026 03:30 PM